CDC25A and non-Hodgkin lymphoma: Due to its proto-oncogenic properties, overexpression of CDC25A has been observed in various malignancies, including Non-Hodgkin Lymphoma and esophageal, gastric, lung, thyroid, head, and neck cancers [38].